Find a Doctor or Practice Location

Are you a referring physician?
I am searching for a
Reset Form
Anthony R. Mato, MD

Anthony R. Mato, MD Physician

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Mato is a Penn Medicine employed physician.

Clinical Specialties


  • Medicine
    • Hematology
    • Medical Oncology

Programs & Centers:

Board Certification:

  • Hematology, 2008
  • Internal Medicine, 2005
  • Medical Oncology, 2008

Clinical Expertise:

  • Chronic Lymphocytic Leukemia (CLL)
  • Lymphoma

Practice Locations and Appointments

  • Abramson Cancer Center

    Perelman Center for Advanced Medicine West Pavilion, 2nd Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: State University of New York at Buffalo
Residency: Hospital of the University of Pennsylvania
Fellowship: Hospital of the University of Pennsylvania


American College of Physician Executives, National American Society of Clinical Oncology, National American Society of Hematology, National

Hospital Affiliation

Dr. Mato is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.


Selected Publications:

Asher Chanan-Khan, Paula Cramer, Fatih Demirkan, Graeme Fraser, Rodrigo Santucci Silva, Sebastian Grosicki, Aleksander Pristupa, Ann Janssens, Jiri Mayer, Nancy L Bartlett, Marie-Sarah Dilhuydy, Halyna Pylypenko, Javier Loscertales, Abraham Avigdor, Simon Rule, Diego Villa, Olga Samoilova, Panagiots Panagiotidis, Andre Goy, Anthony Mato, Miguel A Pavlovsky, Claes Karlsson, Michelle Mahler, Mariya Salman, Steven Sun, Charles Phelps, Sriram Balasubramanian, Angela Howes, Michael Hallek: Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study The Lancet Oncology 17 (2): 200,2016.

Emily C Ayers, Sara Fardin, Saeid Gholami, Abass Alavi, Anthony R Mato: Personalized Management Approaches in Lymphoma: Utility of Fluorodeoxyglucose-PET Imaging PET Clinics : 2016.

Clinton Yam, Daniel J Landsburg, Kevin T Nead, Xinyi Lin, Anthony R Mato, Jakub Svoboda, Alison W Loren, Noelle V Frey, Edward A Stadtmauer, David L Porter, Stephen J Schuster, Sunita D Nasta: Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas American Journal Of Hematology : 2016.

Sharman Jeff P, Mato Anthony R, Keating Michael J: Ibrutinib for Chronic Lymphocytic Leukemia. The New England journal of medicine 374 (16): 1592-1595,2016.

Prioty Islam, Catherine Daniel, Lauren Strelec, Adam H. Kaye, Sarah Brooks, Sunita Nasta, David L. Porter, Jakub Svoboda, Chadi Nabhan, Stephen J. Schuster, Anthony R. Mato: Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia BLOOD 127 (8): 1064-7,2016.

Marco Ruella, Saad S Kenderian, Olga Shestova, Joseph A. Fraietta, Sohail Qayyum, Qian Zhang, Marcela V. Maus, Xiaobin Liu, Selene Nunez-Cruz, Michael Klichinsky, Omkar U Kawalekar, Simon F. Lacey, Michael Milone, Anthony R. Mato, Stephen J Schuster, Michael Kalos, Carl H. June, Saar Gill, and Mariusz A Wasik.: The Addition of the BTK inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clinical Cancer Research : 2016.

Steven Michael Bair, Lauren E. Strelec, Sunita Nasta, Anthony R. Mato, Daniel Jeffrey Landsburg, Edward Allen Stadtmauer, Alison W. Loren, Stephen J. Schuster, Jakub Svoboda: Outcomes in patients with relapsed/refractory Hodgkin lymphoma (RR-HL) with progression after autologous stem cell transplantation in the current era of novel therapeutics Journal of Clinical Oncology 34, 2016 (suppl; abstr 2543) : 2016.

Jeffrey Alan Jones, William G. Wierda, Michael Y. Choi, Matthew Steven Davids, Bruce D. Cheson, Richard R. Furman, Nicole Lamanna, Paul M. Barr, Herbert Aaron Eradat, Ahmad Sami Halwani, Leonard T. Heffner, Brenda Chyla, Ming Zhu, Jalaja Potluri, Maria E. Verdugo, Rod Humerickhouse, Anthony R. Mato, Steven Coutre: Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib Journal of Clinical Oncology 34, 2016 (suppl; abstr 7519) : 2016.

Stephen J. Schuster, Jakub Svoboda, Sunita Nasta, Elise A. Chong, David L. Porter, Daniel Jeffrey Landsburg, Anthony R. Mato, Vijay G. Bhoj, Michael Milone, Simon F. Lacey, Lauren E. Strelec, Alice Y. Zhou, Jan J. Melenhorst, Anne Chew, Jens Hasskarl, Mariusz A. Wasik, Katherine Marcucci, Zhaohui Zheng, Bruce Levine, Carl H. June: Recovery of humoral immunity in patients with durable complete responses following chimeric antigen receptor modified t cells directed against CD19 (CTL019) Journal of Clinical Oncology 34, 2016 (suppl; abstr 7564) : 2016.

Colleen Timlin, Rahul Banerjee, Christina Howlett, Chaitra Shankar Ujjani, Alan P. Skarbnik, Molly Fanning, Stephen J. Schuster, Jakub Svoboda, David L. Porter, Sunita Nasta, Edward A. Stadtmauer, Daniel Jeffrey Landsburg, Tatyana Feldman, Allison Rago, Colleen Dorsey, Donna L. Capozzi, Jennifer Morganroth, Andre Goy, Bruce D. Cheson, Anthony R. Mato: Comparable outcomes in CLL patients treated with reduced-dose ibrutinib: Results from a multi-center study Journal of Clinical Oncology 34, 2016 (suppl; abstr 7529) : 2016.

Academic Contact Info

Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-160
3400 Civic Center Blvd

Philadelphia, PA 19146
Phone: (215) 615-7361
Fax: (215) 615-5888
Patient appointments: 800-789-PENN (7366)

Related Links